Gene
CYSLTR2
cysteinyl leukotriene receptor 2
Explore in graph →CI-GENE-00042860HGNC:18274 ENSG00000152207 NCBI 57105 CIViC Cancer geneApproved
Curated evidence
Clinical evidence (1)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27089179
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CYSLTR2 L129Q1 | ||||||||
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID10010Analysis of genomic data from 136 uveal melanoma samples identified a hotspot mutation in CYSLTR2 that is mutually exclusive with the more common GNAQ and GNA11 mutations. CYSLTR2 L129Q expression in … (full text at CIViC) PMID 27089179 · Moore et al., 2016 · Open in CIViC | civic |
Cohorts
Alteration frequency by cohort (19)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
gdcProvenance
- Source
- NCI Genomic Data Commons (open aggregated data)
- Dataset
- GDC top mutated genes by project
- Version
- Data Release 46.0
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- cohort
- License
- Open-access GDC data (NCI); citation of GDC and originating program requested
- Run
- ING-GDC-20260908-000001
| Cohort | Mapped cancer | Alteration | Affected (n) | Profiled (n) | Frequency (%) | Rank in cohort | Source |
|---|---|---|---|---|---|---|---|
| Sarcoma TCGA-SARC | Sarcoma | Ssm | 152 |
Literature
Linked publications (0)
Data not yet available
No publication linked to this gene yet.